PKM and neoplasm: Analysis of the TCGA AML cohort (TCGA, NEJM, 2012) indicated that patients exhibiting high PKM and G6PD levels exhibit a bad prognosis and lower overall survival, confirming that overexpression of these metabolic enzymes is linked to tumor growth and leukemia expansion.